Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV000518150 | SCV000612690 | likely benign | not provided | 2019-10-31 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000559318 | SCV000652743 | benign | Congenital myopathy with internal nuclei and atypical cores | 2024-01-25 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000518150 | SCV001870260 | benign | not provided | 2020-10-28 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004601192 | SCV005099152 | uncertain significance | Inborn genetic diseases | 2024-05-01 | criteria provided, single submitter | clinical testing | The c.384G>T (p.E128D) alteration is located in exon 4 (coding exon 4) of the CCDC78 gene. This alteration results from a G to T substitution at nucleotide position 384, causing the glutamic acid (E) at amino acid position 128 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV003915450 | SCV004739443 | likely benign | CCDC78-related disorder | 2019-05-22 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |